The endocrine system in chronic nitric oxide deficiency

Félix Vargas, Juan Manuel Moreno1, Rosemary Wangensteen2, Isabel Rodríguez-Gómez and Joaquín García-Estan3

Departamento de Fisiología, Facultad de Medicina, Universidad de Granada, E-18012 Granada, Spain, 1Servicio de Nefrología, U. Experimental, Hospital Virgen de las Nieves, Granada, Spain, 2Área de Fisiología, Universidad de Jaén, Jaén, Spain and 3Departamento de Fisiología, Facultad de Medicina, Universidad de Murcia, Murcia, Spain

(Correspondence should be addressed to F Vargas; Email: fvargas@ugr.es)

Abstract

The experimental model of chronic inhibition of nitric oxide (NO) production has proven to be a useful tool to study cardiovascular and renal lesions produced by this type of hypertension, which are similar to those found in human hypertension. It also offers a unique opportunity to study the interaction of NO with the humoral systems, known to have a role in the normal physiology of vascular tone and renal function. This review provides a thorough and updated analysis of the interactions of NO with the endocrine system. There is special focus on the main vasoactive factors, including the renin-angiotensin-aldosterone system, catecholamines, vasopressin, and endothelin among others. Recent discoveries of crosstalk between the endocrine system and NO are also reported. Study of these humoral interactions indicates that NO is a molecule with ubiquitous function and that its inhibition alters virtually to all other known regulatory systems. Thus, hypothyroidism attenuates the pressor effect of NO inhibitor N-nitro-L-arginine methyl ester, whereas hyperthyroidism aggravates the effects of NO synthesis inhibition; the sex hormone environment determines the blood pressure response to NO blockade; NO may play a homeostatic role against the prohypertensive effects of mineralocorticoids, thyroid hormones and insulin; and finally, NO deficiency affects not only blood pressure but also glucose and lipid homeostasis, mimicking the human metabolic syndrome X, suggesting that NO deficiency may be a link between metabolic and cardiovascular disease.

Introduction

Over the past 15 years, numerous experimental studies have demonstrated the diverse functions and roles of nitric oxide (NO) in normal physiology and in different disease states. NO is known to be synthesized in many cells and tissues by actions of NO synthases (NOS), which catalyze the conversion of L-arginine into L-citrulline with NO as the product. NO mediates its effects by rapid penetration of the target cell membrane and stimulation of soluble guanylate cyclase to produce its second messenger, cyclic guanosine monophosphate (cGMP). Acute, and chronic administrations of L-arginine analogs, which non-specifically inhibit NOS isoforms, are associated with renal and cardiovascular functional and structural alterations that have been studied in detail over the past years. Thus, a new NO-deficient model of arterial hypertension based on chronic use of these inhibitors, e.g., N-nitro-L-arginine methyl ester (L-NAME), has allowed researchers to study the role of NO in the long-term control of blood pressure (BP) and its interactions with the other humoral mediators that control vascular tone and renal function. Several articles can be recommended to the interested reader for an account of the hypertensive model itself (1–3). The present review focuses on the interaction between NO and the endocrine system, and on the role of the hormones directly or indirectly related to BP control in the pathophysiology of NO-deficient arterial hypertension.

Vasoactive hormones

The renin-angiotensin system (RAS)

Many in vivo and in vitro studies have been performed to characterize the physiological role of NO in the control of renal renin synthesis and secretion. Several in vitro studies using different preparations have provided evidence that NO might act as an inhibitor of renin release. Thus, NO inhibition of renin release was reported by Vidal et al. (4) in a bioassay of cortical slices of canine kidney superfused with a solution flowing through the carotid artery and by Greenberg et al. (5) in their study of isolated juxtaglomerular granular cells. However, other in vitro studies of afferent arterioles isolated from rat kidney (6) or isolated perfused kidneys (7) suggested that NO stimulates the synthesis and/or secretion of renin. These discrepancies may be related to the presence of two enzymes,
endothelial NOS (eNOS) and neuronal NOS (nNOS), with different localizations in the kidney and producing the same product NO. The activity of eNOS and macula densa nNOS show opposite responses to changes in the extracellular volume in order to restore the sodium balance and it has even been proposed that endothelium-generated NO directly inhibits macula densa nNOS (8). Endothelium-derived NO appears to be important for buffering minute-to-minute variations in perfusion pressure and rapid changes in angiotensin II activity. In contrast, macula densa nNOS has been proposed to regulate adaptation to long-term changes in distal delivery and is considered a mediator of renin formation (8). Macula densa nNOS expression is regulated in parallel with renin expression under a variety of conditions (9, 10). Macula densa nNOS and renin expression increased in rats treated with furosemide for 5 days and in rats placed on a low sodium diet (9). nNOS has also been shown to be sensitive to sodium intake, which was negatively related to nNOS and renin expression in renal cortical slices from salt-restricted, normal, and salt-loaded rats (10).

The increase in renin release during an acute decrease in perfusion pressure was inhibited by non-selective NOS inhibition in conscious dogs (11). However, administration to rats of 7-nitroindazole, a relative inhibitor of NOS, which fully inhibited a furosemide-induced increase in renin secretion, did not modify renin release after acute decrease in perfusion pressure in rats (12). Although these acute studies indicate an important role for NOS-derived NO in the stimulation of renin release, chronic administration of 7-nitroindazole (4–6 weeks) to normal rats increased plasma renin activity and did not modify inhibitory effects on renin release, induced by chronic desoxycorticosterone (DOCA) administration or by changes in sodium intake (13, 14).

Plasma renin activity (PRA) shows a heterogeneous pattern in nitric oxide (NO) inhibition-induced arterial hypertension in rats (1). Nevertheless, many animal studies have indicated that the RAS plays an important role in this type of hypertension, presenting evidence of a functional balance between angiotensin II (AII) and NO (15, 16).

The acute administration of AII inhibitors to L-NAME hypertensive rats has yielded contradictory results. Thus, Zanchi et al. (9) obtained a large BP reduction with angiotensin type 1 (AT1) receptor blockade, whereas other authors (17, 18) observed less effect of AII blockade on BP or renal hemodynamics in rats with chronic NOS inhibition. Although studies of acute inhibition of AII in the chronic NOS inhibition model have yielded inconclusive results, the participation of the RAS in this type of hypertension is supported by data showing that chronic RAS blockade prevents or attenuates and reverses L-NAME hypertension in rats. Thus, in the first study of this model of hypertension, Ribeiro et al. (19) showed that chronic co-administration of the AT1 receptor antagonist losartan to rats chronically treated with L-NAME, prevented both the hypertension and the renal injury associated with this model, suggesting a key participation of the RAS in these events. These findings were confirmed and extended by several laboratories using chronic administration of AII receptor antagonists or angiotensin-converting enzyme (ACE) inhibitors (20–22). In addition, chronic AII blockade reversed established hypertension (23) and reduced remaining BP elevation after NO inhibition withdrawal (24). Chronic administration of an AT1 antagonist or ACE inhibitor prevented arterial hypertension, as reported above, and improved renal hemodynamics, but the pressure-diuresis and -natriuresis responses were not normalized, despite normalization of the elevated BP and showed very similar slopes to those of hypertensive untreated rats (22). According to these observations, although angiotensin blockade reduces BP, it is not able to overcome renal alterations produced by NO deficiency.

ACE and neutral endopeptidase (NEP) are cell membrane-bound zinc metalloendopeptidases with close homology at their catalytic sites and several common substrates (25). Omapatrilat is a mercaptoacetyl derivative of a dipeptide surrogate that simultaneously inhibits both ACE and NEP in vitro (25) and in vivo (26). Inhibition of NEP protects vasodilator peptides (natriuretic peptides, bradykinin, and adrenomedullin) from degradation and reduces BP in low renin states (27–29). ACE inhibition attenuates the formation of AII and lowers BP in low, normal, and high renin experimental models of hypertension in rats (27) and in spontaneously hypertensive rats (30). Omapatrilat exerts important preventive effects on hypertension and renal injury in rats treated with L-NAME plus DOCA (31), which would be due to vasopeptidase inhibition since chronic AII blockade is completely ineffective in this experimental model (19).

In summary, experimental evidence obtained from in vitro or acute experiments indicates that the NO signal from macula densa cells is very important for renin release. Thus, macula densa cells are rich in nNOS and macula densa nNOS expression is regulated in parallel with renin expression under various situations that increase or decrease renin secretion. However, doubts about the role of nNOS in the long-term control of renin secretion have been raised by chronic studies showing that nNOS blockade does not interfere with the counterbalance between renin and an increased sodium intake or retention. Regarding the role of the RAS in BP and other cardiovascular and renal manifestations after NO blockade, acute experiments yielded contradictory results but chronic studies blocking the RAS, indicated that this system plays a major role in NO-inhibition-induced hypertension. In fact, a functional balance exists between NO and AII, suggesting that AII predominates and promotes cardiovascular and renal injury in clinical diseases with reduced NO production, such as diabetes or atherosclerosis.
**Catecholamines**

NO is hypothesized to be an inhibitory modulator of central sympathetic nervous outflow, and deficient neuronal NO production is thought to cause sympathetic overactivity that can contribute to NO-deficient arterial hypertension (32). This has led to speculation that NO-deficient hypertension is caused not only by attenuation of endothelium-dependent vasodilation but also by inhibition of NO production at other sites (32). Elevated plasma norepinephrine and epinephrine concentrations were found in L-NAME hypertensive rats (9, 33), whereas Liu et al. (34) reported unchanged plasma catecholamine levels and decreased urinary levels of norepinephrine and epinephrine.

Studies of the effects of sympathetic blockade on the acute BP response to NOs inhibition have also yielded contradictory results. Some studies in conscious (35) or anesthetized rats (36) identified a major neurogenic component in the BP elevation, induced by acute NOs inhibition, whereas other studies (37, 38) drew diametrically opposed conclusions.

Acute inhibition of the adrenergic system in the L-NAME hypertension rat model has also produced variable results with a substantial fall (9) and less change in BP (18) both reported during acute α1-adrenergic blockade. On the other hand, acute ganglionic blockade produced a larger fall in BP in rats with chronic NOs inhibition than in controls (39). Short-term sympathectomy attenuated the hypertension induced by 6 days of L-NAME administration in rats (40), suggesting that increased central sympathetic drive may be involved in chronic NOs inhibition-induced hypertension. Sander and Victor (32) also evaluated the contribution of the adrenergic system in the acute (30 min and 6 h) and early (6 days) phases of NO-deficient hypertension and suggested that the neurogenic component increases overtime and that an intact adrenergic system is necessary for the full expression and maintenance of this type of hypertension. In consonance with this finding, it was demonstrated that the hypertension of diabetic L-NAME-treated rats depends on an intact sympathetic nervous system (41). Our group reported that long-term administration of the α1-receptor antagonist prazosin markedly attenuates hypertension and renal injury in chronically L-NAME-treated rats, suggesting that adrenergic tone plays an important role in the long-term control of BP and in renal abnormalities after NO blockade. It is interesting to note that prazosin also exerts important preventive effects on hypertension and renal injury in rats treated with L-NAME plus DOCA (42), transforming L-NAME hypertension into an AIH-independent model in, which chronic AIH blockade is completely ineffective (21). These findings indicate that when PRA is suppressed by DOCA in L-NAME hypertension, the increased BP and renal injury are largely dependent on the adrenergic system.

Available data appear to indicate that sympathetic overactivity follows NO inhibition and that the sympathetic nervous system plays a major role in the hypertension induced by chronic NO inhibition, especially when the RAS is suppressed. Moreover, a counterbalance between NO and the sympathetic nervous system is suggested, as occurs with the RAS and other vasoconstrictor systems.

**Vasopressin**

Several studies have demonstrated an important role for nNOS in the regulation of drinking behavior in rats (43). Our group reported that administration of the nNOS inhibitor 7-nitroindazole (7NI) (44, 45) to normal rats produced a mild polyuria-polydipsia syndrome (13). This phenomenon has been attributed to an inhibitory effect of 7NI on the release of arginine vasopressin (AVP), because nNOS and AVP are co-localized in supraoptic and paraventricular nuclei (43), and other forebrain structures that participate in the regulation of drinking behavior. Moreover, the systemic administration of 7NI was shown to inhibit the increase in plasma AVP produced by salt loading in rats (46) and to reverse the elevated AVP induced by cirrhosis in rats (47).

In chronic L-NAME-treated rats, plasma AVP levels have been reported to be unchanged (34), whereas our group observed that total urinary excretion of immunoreactive AVP was significantly increased (48). However, when these animals received 1% NaCl as drinking fluid, L-NAME treatment produced no additional increase in urinary AVP excretion, greater than that produced by the increased saline intake, despite producing a greater BP increase (48).

At vascular level, the active wall tension of resistance mesenteric arteries from rats treated with L-NAME for 4 weeks showed an unaltered responsiveness to vasopressin (49).

All of these results suggest that vasopressin does not play an important role in BP elevation under chronic NO deficiency. However, further studies using specific blockers of AVP receptors are required to determine the contribution of this vasoactive hormone to the increased BP and renal injury that follows NO inhibition.

**Endothelin**

Vanhoutte et al. (50) proposed an interaction between endothelium-derived vasorelaxing and vasoconstricting factors. Studies of porcine aorta have shown that NO downregulates endothelin (ET)-1 expression by endothelial cells, may blunt the release of ET (51) and is a potent antagonist of endothelin-induced stimulation of vascular smooth muscle (52). Thus, NO has been described as a physiological antagonist of ET-induced contractions (50) that is, therefore able to participate in
the cardiovascular effects induced by NO inhibition. The pressor effect induced in rats by acute NO inhibition with L-NAME injection is attenuated by ET blockade but is very dependent on the activation of endothelin receptors (53–55). Bosentan, an ET inhibitor, acutely decreased BP in L-NAME hypertensive rats (56). However, chronic ET blockade did not alter the arterial hypertension exhibited by the chronic NO deficiency rat model (56–59) and mesenteric resistance arteries showed unchanged responsiveness to ET in rats under chronic L-NAME treatment for 4 weeks (49). Hence, these data and those showing that chronic L-NAME does not increase plasma ET levels (58, 59) or ET-1 mRNA levels in rat aorta or mesenteric arteries (60) suggest that ET does not participate in developing or maintaining the hypertension produced by chronic NO inhibition in the rat. In contrast, with the unchanged plasma values, increased levels of urinary ET excretion have been reported in L-NAME-treated rats (58, 61), suggesting that urinary ET derives from the kidney (33, 58, 59) and supporting an interaction between NO and ET, at least at renal level. Given the profound renal effects of ET, i.e., decreased glomerular filtration rate (GFR) and renal blood flow (RBF) (62), our group proposed its possible involvement in developing and maintaining the renal dysfunction associated with chronic NO deficiency (61). In fact, chronic treatment with bosentan did not attenuate the arterial hypertension of L-NAME-treated rats but normalized GFR and RBF (63), suggesting that the renal vasoconstriction observed in the L-NAME hypertensive rat is related to elevated intrarenal levels of this vasoconstrictor. However, in spite of the beneficial effect of bosentan on the reduced renal hemodynamics of L-NAME-treated rats, this treatment did not normalize the excretory function, which was only moderately increased. These observations suggest that the lower pressure-diuretic- and natriuretic responses of L-NAME hypertensive rats is mainly due to an enhanced tubular reabsorption, since the GFR and RBF normalization observed with bosentan was not sufficient to normalize the elimination of sodium and water, although chronic bosentan significantly improved the pressure-natriuretic response (63).

In summary, published results indicate that ET participates in the renal hemodynamic and excretory alterations produced by the chronic inhibition of NO synthesis. However, the BP increase in this model is not mediated by ET activation. Therefore, the proposed interaction between NO and ET appears to occur solely at renal level, where it participates in the renal dysfunction produced by chronic NO deficiency but not in long-term BP control.

**Thyroid hormones**

Endothelial NOS expression in thyroid follicular cells and the variation in its immunoreactivity suggest a possible role for NO in thyrocyte function and/or growth. eNOS immunoreactivity was detected not only in vascular endothelial cells but also in thyroid follicular cells (64) and eNOS mRNA levels were significantly higher in tissues from hyperthyroid versus euthyroid or hypothyroid patients. Treatment with sodium nitroprusside, a precursor of NO, increased cGMP in primary human thyrocytes (65, 66) and large amounts of NO were produced by human thyroid follicles in culture (67). However, thyroid hormone levels were not affected in chronic NO deficiency. Thus, FT4 and FT3 levels were similar between control rats (FT3 = 1.61 ± 0.10, FT4 = 2.88 ± 0.43) and rats treated with L-NAME 75 mg/100 ml in drinking water for 4 weeks (FT3 = 1.84 ± 0.09, FT4 = 2.79 ± 0.28).

Thyroid gland activity affects acute and chronic pressor responsiveness to L-NAME administration. Thus, hypothyroidism induced by the antithyroid drug methimazole reduced acute pressor responsiveness to L-NAME injection in rats (68). Moreover, oral administration of methimazole maintained normal BP levels in L-NAME-treated rats at 25 days after induction of hypertension. These data agree with reports of a BP reduction in several models of experimental hypertension after treatment with thyroidectomy and antithyroid drugs (69–71) and with more recent evidence of the successful use of antithyroid treatments to prevent spontaneous (72, 73), DOCA-salt (74, 75), Goldblatt two kidney-one clip and low-renal mass (76, 77) arterial hypertension in rats. However, methimazole treatment was unable to reduce BP in L-NAME hypertensive rats after 5 weeks of hypertension induction. These data are similar to those obtained in other models in which antithyroid treatments also failed to normalize blood pressure in the established phase of genetic (72), DOCA-salt (70) and Goldblatt two kidney-one clip (78) hypertension in rats. The latter findings contrast with observations in a low-renal mass model that methimazole-induced hypothyroidism was equally effective in decreasing BP during both early and established phases of hypertension (76). The reasons for the discrepant effects of hypothyroidism in the established phase of hypertension have not been investigated, although morphological changes and modifications in collagen synthesis or distribution in the vascular wall may be involved (79).

Methimazole administration produced marked reductions in heart weight (HW) and in HW to body weight (BW) ratio in early and established phases of L-NAME hypertension, giving rise to a dissociation between cardiac hypertrophy and hypertension in the established phase (68). This dissociation was also observed in Goldblatt two kidney-one clip hypertension (78) and in DOCA-salt (70) hypertension, where hypothyroidism reversed cardiac hypertrophy regardless of the effect on BP.

Gains in BW are known to be reduced in rats in, which a hypothyroid state has been induced (80). In
fact, rats treated with L-NAME plus methimazole in the early and established phases showed decreased BW when compared with rats given L-NAME alone (68). Furthermore, a reduction in BW is known to be accompanied by a decrease in BP (81). Hence, the reduction in BW produced by methimazole in rats might play a role in its antihypertensive effect. However, the reduced BW and high BP levels observed in the L-NAME plus methimazole group in the established phase suggests that the BP reduction observed after methimazole treatment is not due to a non-specific effect on the BW (68).

In summary, presence of a hypothyroid state in the rat reduces the pressor effect after acute NO inhibition and prevents L-NAME hypertension but is unable to reverse L-NAME hypertension in rats. Moreover, hypothyroidism reduces relative cardiac hypertrophy in chronically L-NAME-treated rats. However, the mechanism by which hypothyroidism produces these effects requires further investigation.

The administration of T4 to rats produces a dose-related increase in BP and heart rate (82). It has been reported that rats treated with T4 at a dose that produces a slight increase in BP become hypertensive after partial NOS inhibition with a dose of L-NAME that does not modify BP in control rats. These results indicate that NO may have a counter-regulatory homeostatic role against the prohypertensive effects of thyroid hormone (83).

As the RAS plays an essential role in T4-induced hypertension (84, 85) and because NO may interfere with the prohypertensive effects of Ang II (15, 16), partial NO blockade may result in predominance of the pressor effects of Ang II. In fact, the administration of losartan produced a marked reduction of BP in rats treated with T4 plus NAME, indicating that Ang II plays an important role in this type of hypertension (83). These observations suggest that an increased NOS activity may play a protective homeostatic role against the prohypertensive effects of thyroid hormone. An important factor in the putative antihypertensive mechanisms of NO is its antagonistic effects on the pressor actions of Ang II, since administration of losartan greatly attenuated the BP increase in rats treated with T4 plus L-NAME. Moreover, our group observed that acute L-NAME administration to hypertensive hyperthyroid rats which had a lethal effect that was not observed in normal rats (86).

Based on the data reported in this section, it can be concluded that hypothyroidism attenuates the prohypertensive and cardiotoxic effects of the NO inhibitor L-NAME, whereas hyperthyroidism aggravates the effects of NO synthesis inhibition. Moreover, NO has been shown to play a major role in buffering prohypertensive actions of thyroid hormones (Table 1).

### Table 1

<table>
<thead>
<tr>
<th>Vasoactive hormones</th>
<th>Acute</th>
<th>Long-term</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arginine</td>
<td>Controversial</td>
<td>Controversial</td>
</tr>
<tr>
<td>Sildenafil</td>
<td>Unchanged</td>
<td>Unchanged</td>
</tr>
<tr>
<td>Vasopressin</td>
<td>Unchanged</td>
<td>Unchanged</td>
</tr>
<tr>
<td>Endothelin</td>
<td>Unchanged</td>
<td>Unchanged</td>
</tr>
<tr>
<td>CYP-derived (20 HETE)</td>
<td>Unchanged</td>
<td>Unchanged</td>
</tr>
<tr>
<td>Arachidonic acid metabolites</td>
<td>Unchanged</td>
<td>Unchanged</td>
</tr>
</tbody>
</table>

No, nitric oxide; *, not measured; ↑, increased; ↓, decreased; ..., unchanged.

The endocrine system in chronic NO deficiency
Sex hormones

Epidemiological, clinical, and experimental reports have shown that male subjects are more likely to develop hypertension than females (87, 88). Numerous studies have suggested that the mechanism by which estrogens attenuate arterial hypertension in females is due to an enhancement of NO activity (89–91). However, our group observed that male rats develop higher BP, compared with females after L-NAME administration and that the level of hypertension produced is greater in male rats, at least within the first 5 weeks (92). These observations demonstrate that the sexual dimorphic pattern of BP in rats persists, despite NO blockade (92). These data agree with results published by Verhagen et al. (93) using L-NNA, another NOS inhibitor. However, these findings conflict with a report (94) that showed no difference in BP between males and females treated with L-NAME, although the duration of the study was shorter (2 weeks), a lower dose (3–4 mg/kg per day) of L-NAME was used and BP was measured at only one time point and under anesthesia.

Gonadal hormones play a role in determining the different BP levels produced in males and females. Castration attenuates the sexual dimorphic pattern of BP in L-NAME hypertension. Thus, orchidectomy of L-NAME-treated rats was associated with a reduction in BP to levels found in females, whereas ovariectomy did not affect the level of BP reached in females (92). This suggests that the attenuated hypertension in female is not due to a protective effect of estrogen but rather to a lack of androgens. These observations are consistent with previous findings in SHR (95, 96) and secondary types of hypertension (97–99), which showed that orchidectomy significantly attenuated the BP elevation in the male SHR, while ovariectomy had no effect on the development of hypertension in the female.

Estrogenization of males induced by 17β-estradiol and androgenization of females produced by testosterone administration suppressed the dimorphic pattern of BP in L-NAME hypertension (92). Estrogenization of castrated males produced a reduction of BP similar to that in intact female L-NAME-treated rats (92). However, androgenization of castrated female rats did not change BP in comparison with intact female L-NAME-treated rats (92). The failure of testosterone to affect the development of L-NAME hypertension in castrated female rats is consistent with previous results using the DOCA-salt model (100) and suggests a resistance to the prohypertensive effects of testosterone in females.

Data from different authors indicate that androgens promote exacerbation of hypertension in male humans (101) and animals (102, 103) via a mechanism involving RAS (104, 105). Because PRA is greater in intact male than female L-NAME-treated hypertensive rats and neutering produced similar PRA levels in all groups, it was proposed that renin might be involved in the gender differences of this type of hypertension (92).

In this context, as reported above, there is considerable evidence of a major role for RAS in L-NAME hypertension and experiments have shown that blockade of the RAS prevents development of this model of hypertension (1, 21, 22).

Intact female L-NAME-treated rats showed a higher degree of cardiac hypertrophy than males, despite having a lower BP (92). This dimorphic pattern disappeared with the castration of both males and females and with the androgenization of females or estrogenization of males (92). Therefore, these data indicate that female L-NAME rats have a greater sensitivity to develop cardiac hypertrophy in response to an increased BP when estrogen is present.

Testosterone and estrogen receptors have both been detected in the kidney (106) and sex hormones can directly influence many processes implicated in the pathogenesis of renal disease. Male L-NAME-treated hypertensive rats showed an increased proteinuria that was not present in female rats (92). The dimorphic pattern of proteinuria disappeared with the castration of male and female rats, and testosterone induced the animals to develop proteinuria, regardless of the BP level (92).

Available data indicate that male rats are more sensitive to the pressor and proteinuric effects of chronic NO inhibition, whereas females are more sensitive to develop cardiac hypertrophy. There is evidence that the RAS may play an important role in the dimorphic patterns of BP and proteinuria in this type of hypertension. It has also been reported that testosterone has important proteinuric effects, regardless of increased BP.

Mineralocorticoids

Chronic administration of the mineralocorticoid DOCA induces sodium retention and, in presence of a high salt intake, produces a volume-dependent type of arterial hypertension (107). Experimental protocols in vivo (108) and in vitro (109) suggest that basal NO synthesis is augmented in this model of hypertension and that this increased NO synthesis is apparently a compensatory response for preventing increases in vascular resistance during the development of DOCA-salt hypertension in rats. In contrast, a study of isolated kidneys from DOCA-salt hypertensive rats showed a reduced acetylcholine-induced NO release that was improved by oral administration of L-arginine, which did not, however, influence the time course of systolic BP elevation in the DOCA-salt rats (110).

DOCA treatment without salt supplementation did not produce an elevation in BP, consistent with data from Selye’s group on DOCA-salt-induced hypertension (111) and later reports (48, 112). The addition of a subpressor dose of L-NAME to DOCA-treated rats induced a BP increase, indicating that NO may play a
homeostatic role by preventing the pressor effect of DOCA (48). Moreover, when DOCA was added to a pressor dose of L-NAME it produced an additional BP increase and an aggravation of the microalbuminuria and renal parenchymal injury in comparison with rats treated with L-NAME alone (21, 48). These outcomes may result from the combined impact on renal function of DOCA-induced antinatriuretic effects and NO inhibition, which appears to be borne out by the reduced PRA and plasma protein levels present in this experimental group (21, 48). In saline drinking rats, simultaneous administration of DOCA and L-NAME at subpressor dose exacerbated the course of DOCA-salt hypertension (48). These results confirm that partial NO synthesis inhibition disturbs the homeostatic response to an excess of mineralocorticoids.

DOCA administration produced a significant decrease in plasma protein and suppressed PRA of rats simultaneously treated with L-NAME and DOCA, suggesting that DOCA transforms L-NAME hypertension into a volume-dependent type of hypertension (21, 48). In consonance with this, the administration of DOCA interferes with the preventive effects of losartan against the elevated BP and increased microalbuminuria, hyaline arteriopathy, and glomerulosclerosis of L-NAME hypertension (21). However, K-Lallamme et al. (113) reported that losartan prevented the development of hypertension in uninephrectomized saline drinking rats treated with L-NAME, DOCA, or L-NAME plus DOCA over a short 9-day treatment period.

In summary, impaired NO synthesis increases sensitivity to the pressor effect of mineralocorticoids in presence or absence of increased saline intake. Hence, NO contributes to an adaptive response to excess mineralocorticoids, possibly by facilitating natriuresis and thereby controlling BP.

**Insulin**

Several authors have reported that L-NAME hypertension is associated with hyperinsulinaemia and insulin resistance (35). Thus, Erlich et al. (114) showed that L-NAME treatment for 4 weeks resulted in a significant elevation of insulin levels at the end of the experiment, although triglycerides and glucose were unaffected throughout the experiment. They also reported that a combination of L-NAME and verapamil attenuated the hypertension induced by L-NAME and prevented the consequent rise in insulin level. De Angelis Lobo d’Avila et al. (115) observed that L-NAME-induced hypertension was accompanied by an increase in insulin resistance in rats and that exercise reversed peripheral insulin resistance in trained L-NAME-hypertensive rats. However, other authors did not find that acute (116) or chronic (33, 117, 118) L-NAME administration modified plasma concentrations of glucose, insulin, total cholesterol or triglycerides or caused glucose intolerance or insulin resistance. These discrepancies are difficult to explain because the studies used similar doses of L-NAME, duration of experimental procedure and strain of rat.

The most convincing evidence that NO deficiency is related to hyperinsulinaemia and hyperlipidaemia has been provided by studies of disruption of the gene encoding for eNOS. Mice lacking eNOS (−/−) were hypertensive and had fasting hyperinsulinaemia, hyperlipidaemia, and 40% lower insulin-stimulated glucose uptake versus control mice (119). Cook et al. (120) also reported that mice with targeted disruption of eNOS were hypertensive and insulin resistant and showed fasting hyperinsulinaemia and 1.5- to 2-fold increase in plasma concentrations of cholesterol, triglyceride, and free fatty acids. Plasma leptin levels were 30% higher in eNOS (−/−) than wild-type mice. Partial gene deletion of eNOS (+/−) predisposed mice to greater high-fat, diet-induced insulin resistance and arterial hypertension (121). Other laboratories reported that inhibition of NO synthesis increases hypertension during chronic glucose infusion in normal rats (122) and accentuates BP elevation in hyperinsulinemic rats (123, 124).

All of the above results indicate that NO deficiency affects not only BP but also glucose and lipid homeostasis, mimicking the human metabolic syndrome X. Therefore, NO deficiency may be a link between metabolic and cardiovascular disease.

**Paracrine and autocrine compounds**

In the dog kidney, the full renal vasodilatory potential of NO (or prostaglandin (PG) I₂) is expressed only in the presence of prostaglandin (or NO) inhibition, suggesting that each autacoid is mutually antagonistic to the synthesis/release of the other (125). In rats, however, Navarro et al. (33) reported that urinary excretion of PGE₂, 6-ketoprostaglandin F₁₂, and tromboxane B₂ were not significantly affected by L-NAME after 5 weeks of treatment. This is in agreement with the observation that acute cyclooxygenase (COX) inhibition did not aggravate hypertension in rats under chronic L-NAME treatment, although additional renal vasoconstriction was produced (126). However, simultaneous chronic administration of indomethacin plus L-NAME did not further modify the reduced RBF, GFR, diuresis and natriuresis of L-NAME-treated hypertensive rats (127). On the other hand, indomethacin (4 mg/kg per day, 7 days) partially prevented BP elevation, restored responsiveness to phenylephrine, and enhanced sensitivity to acetylcholine in rats (128). These results suggest that constricting factors arising from the COX pathway contribute to the arterial hypertension and altered vascular reactivity that follows chronic inhibition of NO synthase (128). Moreover, it has been reported that inhibition of COX-2 prevented hypertension and proteinuria in L-NAME-treated rats (129). In contrast, to these findings, Muscara et al. (130)
reported that chronic selective COX-2 inhibition produced by the daily administration of celecoxib (10 mg/kg) for 3 weeks elevated the BP of normal and L-NAME-treated rats.

Arachidonic acid (AA) can be metabolized by COX and lipoxygenase enzymes, and a new pathway for its metabolism has recently emerged. Thus, AA is also metabolized by a family of cytochrome P-450 enzymes that catalyze the formation of epoxyeicosatrienoic acid (5 and 6-EET) and 20-hydroxyeicosatrienoic acid (20-HETE), among others. 20-HETE and EETs act as second messengers in vascular and renal function (131). Given the importance of these compounds in the regulation of vascular tone and the renal handling of sodium, numerous studies have addressed their role in the pathogenesis of hypertension. There is wide evidence of the altered vascular and renal production of these factors in several models of experimental hypertension (131, 132). NO and 20-HETE interacted to produce reciprocal inhibition in in vivo and in vitro preparations (131, 133). NO reversibly binds with heme-containing P450 enzymes, inhibiting their activities and hence their products. NO tonically inhibits production of 20-HETE by the P4504A enzyme. The inhibition of the formation of 20-HETE attenuated the acute hypertensive effects and fall in RBF produced by NO blockade in rats (133, 134). The chronic administration of SnCl₂, which induces heme-oxygenase and reduces the activity of all CYP enzymes and therefore 20-HETE production, attenuated the development of L-NAME hypertension in rats (135). Moreover, the administration of ABT, an inhibitor of 20-HETE formation, attenuated BP elevation in SHR-L-NAME-treated rats, improved their impaired responsiveness to noradrenaline and isoprenaline and minimized the morphological alterations in kidney and heart observed in SHR-L-NAME-treated rats without ABT treatment (136). Combined treatment with DDMS, inhibitor of 20-HETE synthesis, attenuated the MAP and RVR increase and the decrease in GFR produced by L-NAME in pregnant rats (137). In contrast, with all of these findings, it was recently reported that CYP-450 induction by administration of benzafibrate, a peroxisome proliferator-activated receptor α, attenuated hypertension, plasma 8-isoprostane and NAD(P)H oxidase (138) in L-NAME-treated rats. Similar contradictory results have been observed in SHR (139, 140) and DOCA-salt hypertensive rats (138, 141), in which inhibition and activation of CYP 450 enzymes attenuated the development of hypertension.

In summary, the role of compounds generated by COX or by CYP-450 enzymes acting on AA in the pathophysiology of NO inhibition-induced hypertension is controversial. The reasons for these discrepant observations have not been defined, but they may be explained by the variety of products with pro- or antihypertensive effects generated by these enzymes.

Other hormones

In the pituitary gland, NO exerts inhibitory actions on prolactin secretion, growth hormone-induced secretion, and gonadotropin-releasing hormone-induced secretion of luteinizing hormone (142–144). However, it is not known whether they participate in chronic L-NAME-induced hypertension.

Concluding remarks

This review presents evidence that NO buffers the prohypertensive effects and renal injuries promoted by classic vasoactive hormones and other hormones related to BP control and renal function, such as thyroid hormones, mineralocorticoids or insulin. These observations are of potential clinical relevance since the association of an excess of these hormones with diseases that course with reduced NO production, such as atherosclerosis, diabetes or essential hypertension, may aggravate their respective pathogenic effects. Moreover, NO deficiency may represent a link between metabolic and cardiovascular disease. Male rats are more sensitive to the pressor and proteinuric effects of chronic NO inhibition, despite the suggestion by numerous authors that estrogens attenuate arterial hypertension in females via NO activity. Evidence is also provided that the RAS may play an important role in the dimorphic patterns of BP and proteinuria in this type of hypertension, and that testosterone has important proteinuric effects, regardless of BP level. Finally, most of the data discussed in this review were generated in rat models treated with L-arginine analogs. A limitation of these data is that in many instances we do not know whether the observed effects were related to inhibition of eNOS-, inducible NOS (iNOS)- or nNOS-derived NO synthesis. Study of this topic together with analysis of the interaction between NO and the hormones at cellular level in the main target organs, i.e., heart, vessels and kidney, open new perspectives for the assessment of cardiovascular diseases that require future investigations.

Acknowledgements

This manuscript was supported by grant SAF2005-06997 from the Spanish Ministry of Education and Science. We are grateful to R Davies for assistance with the English version.

References


28 Gacio LV, Quaschning T, Burnett JC, Jr. & Luscher TF. Vasopeptidase inhibition prevents endothelial dysfunction of resistance arteries in salt-sensitive hypertension in comparison with single ACE inhibition. *Hypertension* 2001 **37** 28–33.


40 Sander M, Hansen J & Victor RG. The sympathetic nervous system is involved in the maintenance but not initiation of the hypertension induced by N\textsuperscript{\textregistered}-nitro-arginine methyl ester. Hypertension 1997 30 64–70.
56 Clozel M & Breu V. The role of ET(B) receptors in normotensive and hypertensive rats as revealed by the non-peptide selective ET(B) receptor antagonist Ro 46-8443. FEBS letters 1996 383 42–45.
76 Andrade J, Haro JM, Jódar E, Luna JD & Vargas F. Effects of methimazole on low renal mass hypertension: changes on blood pressure and pressor responsiveness to vasoconstrictors. Pharmacology 1992 44 315–323.
est (L-NAME), causes hypertension, but not glucose intolerance or insulin resistance, in rats. American Journal of Hypertension 1995 8 1009–1014.


